159 related articles for article (PubMed ID: 2939203)
21. A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. An NCI Canada Clinical Trials Group study.
Skillings J; Cripps C; Eisenhauer E; Pater J; Verma S; Walde D
Invest New Drugs; 1991 Feb; 9(1):79-82. PubMed ID: 1827434
[TBL] [Abstract][Full Text] [Related]
22. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
Larson RA; Geller RB; Janisch L; Milton J; Grochow LB; Ratain MJ
Cancer Chemother Pharmacol; 1995; 36(3):204-10. PubMed ID: 7781139
[TBL] [Abstract][Full Text] [Related]
23. A phase II evaluation of menogaril in cisplatin-refractory advanced ovarian carcinoma. A collaborative trial of the North Central Cancer Treatment Group and the Mayo Clinic.
Long HJ; Laurie JA; Wieand HS; Edmonson JH; Levitt R; Krook JE; Abu-Ghazaleh S
Cancer; 1991 Aug; 68(4):730-2. PubMed ID: 1830238
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of intravenous menogaril in advanced ovarian carcinoma. EORTC Early Clinical Trials Group.
Sessa C; Kaye SB; Renard J; ten Bokkel Huinink W; Cavalli F
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):751-2. PubMed ID: 2523809
[No Abstract] [Full Text] [Related]
25. Phase II evaluation of menogaril in patients with advanced hypernephroma.
Long HJ; Hauge MD; Therneau TM; Buckner JC; Frytak S; Hahn RG
Invest New Drugs; 1991 Aug; 9(3):261-2. PubMed ID: 1838363
[TBL] [Abstract][Full Text] [Related]
26. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of menogaril in adenocarcinoma of the pancreas. A Southwest Oncology Group study.
Brown TD; Goodman PJ; Fleming TR; Baker LH; Macdonald JS
Invest New Drugs; 1991 Feb; 9(1):77-8. PubMed ID: 1827433
[No Abstract] [Full Text] [Related]
28. Tolerance of full dose menogaril (NSC 269148) in patients with abnormal hepatic and renal function.
Conley BA; Egorin MJ; Sinibaldi V; Van Echo DA
Invest New Drugs; 1990 Nov; 8(4):365-7. PubMed ID: 2150671
[No Abstract] [Full Text] [Related]
29. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
30. Menogaril in the treatment of malignant mesothelioma: a phase II study.
Hudis CA; Kelsen DP
Invest New Drugs; 1992 Jul; 10(2):103-6. PubMed ID: 1386842
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
[TBL] [Abstract][Full Text] [Related]
32. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
[TBL] [Abstract][Full Text] [Related]
33. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB
Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
[TBL] [Abstract][Full Text] [Related]
35. Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma. A Southwest Oncology Group study.
Vance RB; Crowley JJ; Macdonald JS; Ahmann FR
Invest New Drugs; 1991 Feb; 9(1):73-5. PubMed ID: 1851143
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504).
Stephens RL; Goodman P; Crawford ED; Spicer CF; Lowe BA; Ahmann FR; Chapman R; Natale RB
Invest New Drugs; 1990; 8 Suppl 1():S69-71. PubMed ID: 2143177
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of menogaril (NSC-269148) in colorectal carcinoma. A Southwest Oncology Group study.
Whitehead RP; Earhart RH; Fleming T; Goodman P; Macdonald JS; Pollock T; Ungerleider JS
Invest New Drugs; 1990 Aug; 8(3):295-7. PubMed ID: 2148743
[TBL] [Abstract][Full Text] [Related]
38. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
Ryan DP; Supko JG; Eder JP; Seiden MV; Demetri G; Lynch TJ; Fischman AJ; Davis J; Jimeno J; Clark JW
Clin Cancer Res; 2001 Feb; 7(2):231-42. PubMed ID: 11234874
[TBL] [Abstract][Full Text] [Related]
39. Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study.
Eisenhauer EA; Pritchard KI; Perrault DJ; Verma S; Pater JL
Invest New Drugs; 1990 Aug; 8(3):283-7. PubMed ID: 2148741
[TBL] [Abstract][Full Text] [Related]
40. Phase II evaluation of menogaril in women with metastatic breast cancer after failure of first-line chemotherapy.
Long HJ; Schaid DJ; Schutt AJ; Ingle JN; Loprinzi CL; Edmonson JH
Am J Clin Oncol; 1988 Oct; 11(5):524-7. PubMed ID: 2972192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
